Clinical trials of Leqembi and donanemab, which is expected to win U.S. approval later this year, have shown that removing beta amyloid can slow cognitive decline in people with early-stage Alzheimer’s. Patient advocates and three neurologists interviewed by Reuters believe the same may be true of people with Down syndrome.
The survey of 502 employers by Accolade, a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.
For Novo Nordisk, Ozempic is the game changer that has propelled the company to new heights, but mastering the supplies of its semaglutide drugs, especially Wegovy, is the current challenge.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
With Humira finally losing exclusivity and market share, a new generation of autoimmune drugs is entering the spotlight at AbbVie.
With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.
For AstraZeneca, the approval of Enhertu last year marked one of the high points in the company’s scientific program.
Boehringer Ingelheim is concentrating on expanding its pipeline beyond Jardiance and other key products.
Retiring BMS CEO Giovanni Caforio is handing off a company orders of magnitude different than it was at the beginning of his tenure.
While the company is no longer enjoying the benefit of enormous sales for its COVID treatment Veklury, Gilead is still doing very nicely, thank you very much.